Additionally, based on the IPS scores, the immunotherapy efficacy of PD-1 inhibitors or CTLA4 inhibitors could be enhanced when combined with anti-CD93 therapy in STAD. This evidence concerns the gene PDCD1 and gastric adenocarcinoma.